ArticleInternational journal of cancer2026
Association Between Socioeconomic Position and Diagnosis, Treatment and Survival of Patients With Stage I-III Rectal Cancer in the Netherlands.
Article in International journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Socioeconomic position (SEP) influences cancer care and outcomes, even in countries with government-funded healthcare. This population-based study examined associations between SEP, rectal cancer care and survival of patients in the Netherlands. Data from 25,995 patients with Stage I-III rectal cancer diagnosed between 2015 and 2023 were obtained from the Netherlands Cancer Registry. SEP was categorised as lower, intermediate or higher using income-based postal code data. Associations between SEP and detection method, treatments, and outcomes were analysed using multivariable logistic regression. Relative survival and relative excess risk (RER) of death were calculated using a generalised linear model. Compared to lower SEP, higher SEP patients were younger (median age 66 vs. 71 years), more often male (65% vs. 59%), had better performance status (71% vs. 52% PS0), fewer comorbidities (63% vs. 50% CCI 0) and lower obesity rates (15% vs. 23%). Higher rates of Stage I tumours (34% vs. 30%), screen-detection (45% vs. 38%), laparoscopic surgery use (93% vs. 90%), and lower rates of colostomies (64% vs. 71%) and adverse in-hospital outcomes (44% vs. 55%) were observed among higher SEP patients (all p < 0.001). Five-year relative survival improved with increasing SEP (79.5% lower, 82.4% intermediate, 84.9% higher SEP; p < 0.001), with lower excess mortality for higher SEP patients (RER 0.90, 95% CI 0.81-0.99). SEP-related differences were observed in screening, stage at diagnosis, surgical treatment and survival. Although several disparities were partly explained by comorbidity and BMI, others persisted, highlighting the need for targeted strategies to reduce differences between SEP groups in rectal cancer management and outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.